QALY = quality-adjusted life year; ICER = incremental cost-effectiveness ratio; base = cheapest alternative; dom = dominated. Results are shown as means and 95% credibility intervals.
In this work, we aimed to assess the impact of clazosentan on clinical labour time costs within Japan’s value-based healthcare system using time-driven activity-based costing. Time-driven activity-bas
IntroductionPatients with a penicillin allergy label (PAL) use more and broader-spectrum antibiotics, have worse health outcomes and cost more to treat than patients without a PAL. A significant propo